Exiqon's Q1 Revenues Decline 13 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Exiqon today reported that its first-quarter revenues fell 13 percent year over year on weak sales in North America.

The Denmark-based genomics tools and molecular diagnostics developer reported total revenues of DKK 24 million ($4.2 million) for the three months ended March 31, compared to DKK 27.6 million for the first quarter of 2011. It said that organic sales growth for research products was 25 percent in Europe, offset by a 33 percent decline in North America, where it said that it is implementing a new sales strategy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.